| 09/23/2026 5:01 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/21/2026 6:04 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/21/2026 5:50 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/18/2026 5:33 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/15/2026 9:24 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/15/2026 9:01 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/14/2026 6:36 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/11/2026 3:05 PM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/08/2026 8:04 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/08/2026 5:29 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 11:08 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Get the Latest News and Ratings for AZNCF and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.
|
| 09/01/2026 11:20 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 6:27 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 6:36 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 6:10 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 6:18 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 6:04 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/27/2026 6:04 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/25/2026 6:03 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/19/2026 8:43 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/17/2026 6:08 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/17/2026 6:15 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/17/2026 6:03 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/07/2026 10:40 AM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/03/2026 9:44 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/03/2026 9:29 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/31/2026 5:54 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/14/2026 5:37 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/09/2026 5:17 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/08/2026 3:30 PM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/01/2026 9:10 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/01/2026 9:06 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/29/2026 1:30 PM | AstraZeneca (901832) Filer | Form 11-K Annual reports of employee stock purchase, savings and similar plans pursuant to Section 15(d) | |
| 06/29/2026 5:45 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/29/2026 5:05 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/16/2026 3:05 PM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/15/2026 5:52 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/01/2026 9:10 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/01/2026 9:06 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/29/2026 5:43 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/28/2026 1:29 PM | AstraZeneca (901832) Subject NEW YORK STOCK EXCHANGE LLC (876661) Filed by | Form 25-NSE | |
Elon gets it. Do you? (Ad) Moderna's stock jumped nearly 200% in a single day after a successful Phase 3 trial for its cancer drug, and Merck added $43 billion to its market cap on the same news.
Porter & Co. says AI-driven drug discovery and automated labs are cutting development timelines by up to 80% and lifting early clinical success rates to 90%, fueling what they call biotech's Ignition Point. Stream the free Ignition Point broadcast for the full biotech breakdown. |
| 05/27/2026 5:04 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/26/2026 6:09 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/26/2026 6:17 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/26/2026 6:02 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/22/2026 3:05 PM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/18/2026 9:15 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/18/2026 8:42 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/18/2026 8:36 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/14/2026 6:25 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/08/2026 3:05 PM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/01/2026 9:23 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/01/2026 7:40 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/01/2026 7:45 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/29/2026 6:23 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/28/2026 10:32 AM | AstraZeneca (901832) Subject VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by | Form SCHEDULE 13G | |
| 04/28/2026 6:31 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/27/2026 5:29 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/23/2026 5:10 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/21/2026 5:19 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/20/2026 6:03 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/09/2026 12:01 PM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/08/2026 1:20 PM | AstraZeneca (901832) Subject NEW YORK STOCK EXCHANGE LLC (876661) Filed by | Form 25-NSE | |
| 04/02/2026 8:27 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/01/2026 9:30 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/31/2026 6:48 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/27/2026 7:04 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/20/2026 6:59 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/19/2026 6:51 PM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/16/2026 7:45 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/10/2026 7:07 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/10/2026 6:37 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/06/2026 7:11 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/06/2026 6:43 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/06/2026 6:50 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/04/2026 8:14 AM | AstraZeneca (901832) Filer | Form CERT | |
| 03/03/2026 3:01 PM | AstraZeneca Finance LLC (1862005) Filer AstraZeneca (901832) Filer | Form 8-A12B | |
| 03/02/2026 11:00 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/26/2026 7:59 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/25/2026 9:40 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/25/2026 7:30 AM | AstraZeneca Finance LLC (1862005) Filer AstraZeneca (901832) Filer | Form 424B2 Transaction specifc information for a delayed shelf offering | |
| 02/24/2026 5:51 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/24/2026 5:45 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/20/2026 5:57 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/10/2026 10:55 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/06/2026 8:48 AM | AstraZeneca (901832) Filed by Innate Pharma SA (1598599) Subject Innate Pharma SA (1598599) Subject | Form SCHEDULE 13D/A | |
| 02/06/2026 8:54 AM | AstraZeneca (901832) Filed by Monopar Therapeutics (1645469) Subject | Form SCHEDULE 13G/A | |
| 02/03/2026 2:21 PM | AstraZeneca (901832) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 02/03/2026 6:01 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/02/2026 12:26 PM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/02/2026 6:51 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Shocking new footage just released (Ad) Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before.
In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years.
Del Real just released a full video breakdown of what is driving this move and how to prepare. Watch Gerardo Del Real's new uranium market breakdown now |
| 02/02/2026 6:25 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/30/2026 5:19 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/29/2026 7:08 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/22/2026 3:28 PM | AstraZeneca (901832) Filer | Form CERT | |
| 01/22/2026 3:22 PM | AstraZeneca Finance LLC (1862005) Filer AstraZeneca (901832) Filer | Form 8-A12B | |
| 01/22/2026 3:14 PM | AstraZeneca (901832) Filer | Form CERT | |
| 01/20/2026 6:18 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/08/2026 5:04 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/02/2026 11:24 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |